BARX2 plays a negative role in regulating the canonical Wnt/β-catenin pathway [29–31] and serves as an anti-oncogene in non-small-cell lung cancer [17, 29], colorectal cancer [34], hepatocellular carcinoma [35], breast cancer [27] and ovarian cancer [28]. This evidence concerns the gene BARX2 and breast carcinoma.